Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data from the study are showing encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, according to the company's press release.
The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination. Quantum BioPharma believes this imaging approach could enhance the development of MS therapies, including its investigational candidate Lucid-MS. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026.
Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis. The imaging study's progress is a key step in potentially validating the tracer as a tool to measure demyelination, which could accelerate clinical development of Lucid-MS and other MS therapies.
The announcement is significant because it provides early evidence that the novel imaging technique may be able to detect both active lesions and gray matter lesions, which are often missed by conventional MRI. If validated, this could improve diagnosis and monitoring of MS, as well as provide a more sensitive biomarker for clinical trials.
For the full press release, visit https://ibn.fm/4IZ0y.
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its subsidiary Lucid Psycheceuticals Inc., the company is advancing Lucid-MS. Additionally, Quantum holds a 19.84% stake in Unbuzzd Wellness Inc. and is entitled to royalty payments from sales of UNBUZZD(TM) products.
Forward-looking statements in this release involve risks and uncertainties, as detailed in the company's SEC filings. More information is available at https://ibn.fm/QNTM.
